Analysis of a peptide hormone–receptor interaction in the yeast two-hybrid system

  1. Jianwei Zhu and
  2. C. Ronald Kahn*
  1. Research Division, Joslin Diabetes Center, and Department of Medicine, Harvard Medical School, Boston, MA 02215
  1. Communicated by Arnold L. Demain, Massachusetts Institute of Technology, Cambridge, MA (received for review April 25, 1997)

Abstract

Interaction between a peptide hormone and extracellular domains of its receptor is a crucial step for initiation of hormone action. We have developed a modification of the yeast two-hybrid system to study this interaction and have used it to characterize the interaction of insulin-like growth factor 1 (IGF-1) with its receptor by using GAL4 transcriptional regulation with a β-galactosidase assay as readout. In this system, IGF-1 and proIGF-1 bound to the cysteine-rich domain, extracellular domain, or entire IGF-1 proreceptor. This interaction was specific. Thus, proinsulin showed no significant interaction with the IGF-1 receptor, while a chimeric proinsulin containing the C-peptide of IGF-1 had an intermediate interaction, consistent with its affinity for the IGF-1 receptor. Over 2000 IGF-1 mutants were generated by PCR and screened for interaction with the color assay. About 40% showed a strong interaction, 20% showed an intermediate interaction, and 40% give little or no signal. Of 50 mutants that were sequenced, several (Leu-5 → His, Glu-9 → Val, Arg-37 → Gly, and Met-59 → Leu) appeared to enhance receptor association, others resulted in weaker receptor interaction (Tyr-31 → Phe and Ile-43 → Phe), and two gave no detectable signal (Leu-14 → Arg and Glu-46 → Ala). Using PCR-based mutagenesis with proinsulin, we also identified a gain of function mutant (proinsulin Leu-17 → Pro) that allowed for a strong IGF-1–receptor interaction. These data demonstrate that the specificity of the interaction between a hormone and its receptor can be characterized with high efficiency in the two-hybrid system and that novel hormone analogues may be found by this method.

Footnotes

  • * To whom reprint requests should be addressed at: Joslin Diabetes Center, Research Division, One Joslin Place, Boston, MA 02215. e-mail: kahnr{at}joslab.harvard.edu.

  • ABBREVIATIONS:
    IGF-1,
    insulin-like growth factor 1;
    GAL4DB,
    GAL4 DNA-binding domain;
    GAL4AD,
    GAL4 activation domain;
    IRR,
    insulin receptor-related receptor;
    InIGF,
    chimeric molecule with the C-peptide of IGF-1 inserted into human insulin;
    IGF1R,
    full-length IGF-1 proreceptor
« Previous | Next Article »Table of Contents